The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The full form of FORTRAN is Formula Translation. It is the first high-level programming language,…
India has many historical forts that tell stories of bravery and power. These forts were…
Unified Payments Interface (UPI) transactions surged to a record high in March 2025, reaching Rs…
India's Goods and Services Tax (GST) collections witnessed a strong growth of 9.9% year-on-year (YoY)…
The Reserve Bank of India (RBI) marks its 90th anniversary in 2025, commemorating nine decades…
Nidhi Tiwari is a renowned Indian Foreign Service (IFS) officer who has made significant contributions…
![](data:image/svg+xml;charset=utf-8,<svg height="218px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
